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Correlation of Ki-67 proliferation index and 18-fluorodeoxyglucose uptake in colorectal
incidental lesions detected by positron emission tomography-computed tomography
1,

2

3

1

Servet GÜREŞCİ *, Özlem ÖZMEN , Metin UZMAN , Gülçin ŞİMŞEK ,
2
4
3
Ebru TATCI , Atila GÖKÇEK , Abdullah Özgür YENİOVA
1
Department of Pathology, Keçiören Training and Research Hospital, Ankara, Turkey
2
Department of Nuclear Medicine, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
3
Department of Gastroenterology, Keçiören Training and Research Hospital, Ankara, Turkey
4
Department of Radiology, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
Received: 06.10.2014

Accepted/Published Online: 13.09.2015

Final Version: 23.06.2016

Background/aim: To investigate whether focal high maximum standardized uptake value (SUVmax) determined by 18-fluorodeoxyglucose
(FDG) positron emission tomography (PET)-computed tomography (CT) imaging is correlated with proliferation index in the colorectal
region.
Materials and methods: SUVmax values of 31 colorectal neoplasms that were incidentally detected during PET-CT examination were
compared to dysplasia degree, histopathologic diagnosis, and immunohistochemical expression of the Ki-67 proliferation marker.
Results: Statistically significant correlations were found between SUVmax and Ki-67 proliferation index, dysplasia degree, and
histopathologic diagnosis. Median SUVmax value was found to be significantly higher in high-risk lesions than low-risk lesions.
Conclusion: The Ki-67 proliferation index is an indicator of SUVmax in colorectal tract. SUVmax values can predict malignancy
and prognosis in this region. Colonoscopy and biopsy should always be performed whenever a focal high FDG uptake is determined
incidentally in a patient.
Key words: Colorectal neoplasm, positron emission tomography, Ki-67 antigen

1. Introduction
18-Fluorodeoxyglucose (FDG) positron emission
tomography (PET)-computed tomography (CT) is
a relatively new technique used for tumor imaging,
staging, and monitoring. Proliferating activity, glucose
transporters, and hexokinase levels can all lead to FDG
accumulation in metabolically active cells (1). In routine
practice FDG PET-CT is better used for staging and
monitoring colorectal carcinoma and rarely for the
primary diagnosis, but incidental colorectal lesions can
be detected on whole-body images that are applied for
many other purposes (2). In this study we evaluated FDG
PET-CT of patients with resected colorectal lesions and
investigated whether metabolic activity was correlated
with proliferating activity, dysplasia degree, and diagnosis.
2. Materials and methods
2.1. Patient selection
This retrospective study was approved by the ethics
committee of Keçiören Training and Research Hospital
* Correspondence: gurescisa@hotmail.com
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(number: B.10.4.ISM.4.06.68.49, date: 28.11.2012). The
medical records of 2521 patients who underwent wholebody imaging by FDG PET-CT for staging of lung
carcinoma between January 2010 and December 2012 in
the Atatürk Chest Diseases and Thoracic Surgery Training
and Research Hospital nuclear medicine department were
retrospectively reviewed. Ninety-eight subjects followed by
colonoscopy within 90 days after FDG PET-CT in the referral
gastroenterology department of the Keçiören Training and
Research Hospital were identified. Colonoscopic evaluation
was generally performed for patients with lung cancer
who could benefit from further treatment or in whom a
metastatic process to the lungs was excluded. Patients with
prior chemo-radiotherapy, inflammatory bowel disease,
incomplete colonoscopy because of insufficient bowel
cleaning, and negative colonoscopy were excluded. Positive
colonoscopic findings corresponding to focal FDG uptake
sites were documented. Finally, histopathologic diagnosis
of 31 lesions from 22 patients that correlated to incidental
focal FDG uptake sites was achieved.
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of colon polyps. When a significant cut-off value was
observed the sensitivity, specificity, and positive and
negative predictive values were calculated. While
evaluating the area under the curve (AUC) a 5% type 1
error was used to accept a statistically significant value
of the test variables. SPSS 17.0 for Windows (SPSS Inc.,
Chicago, IL, USA) was used for the analysis and P < 0.05
was considered significant.
3. Results
The baseline characteristics of the patients are shown
in Table 1. Nine of the 22 patients had two separate (at
least 5 cm apart) foci of increased FDG PET-CT uptake
and corresponding colonoscopic lesions. Histopathologic
diagnoses of the lesions were hyperplastic polyp,
adenomatous polyp (15 tubular adenoma, 2 tubulovillous
adenoma, 2 villous adenoma, 1 traditional serrated
adenoma/polyp), and adenocarcinoma not otherwise
specified. Sixteen lesions showed low-grade dysplasia and
4 high-grade dysplasia among adenomatous polyps.
Median SUVmax and Ki-67 were 6.96 (range: 2.03–
34.37) and 17.2 (range: 4.20–82.6), respectively (Figure
1). Statistical analysis showed significant correlation
between SUVmax and Ki-67 (P < 0.001). The mean Ki67 of the adenocarcinoma group was significantly higher
than both adenomatous and hyperplastic polyps (P <
0.001 and P < 0.001). No correlation was found between
Ki-67 of adenomatous and hyperplastic polyps (P =
0.681). Dysplasia degree and Ki-67 also did not show any
correlation (P = 0.067).
40
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2.2. FDG PET-CT imaging protocol
All the patients underwent whole-body FDG PET using a
Siemens Biograph 6 HI-REZ integrated PET-CT scanner
(Siemens Medical Solutions, Knoxville, TN, USA). The
patients fasted for at least 6 h and serum glucose levels
were confirmed to be less than 180 mg/dL prior to
injection. PET-CT images were obtained 60 min after the
administration of 370–450 MBq (10–15 mCi) of FDG.
Oral contrast material was used in all patients for better
visualization of the intestinal lumens. CT scans that were
used for attenuation correction were performed just before
PET acquisitions. PET data were acquired from the top of
the skull to the upper thigh with the arms in an up position.
The maximum standardized uptake value for body weight
(SUVmax) was calculated by drawing a region of interest
(ROI) on the attenuation-corrected transaxial FDG PET
images.
2.3. Histopathologic evaluation and immunohistochemical
staining
All the slides were reevaluated independently by two
pathologists according to the 2010 World Health
Organization criteria and if there was a disagreement for
the diagnosis or dysplasia degree the decision was made by
consensus (3). Age, sex, location, and diameter of the lesions
were also recorded. A representative area suitable for the
aim of the study was selected for immunohistochemical
analysis.
For immunohistochemical staining 4-µm cut sections
were prepared on adhesive slides from paraffin blocks.
After antigen retrieval by citrate, Ki-67 (Novocastra, NCLMM1, 1/100) primary antibody was applied by indirect
peroxidase method. Positive (nonneoplastic tonsil tissue)
and negative controls were used during the process.
The expression of Ki-67 was quantified by two
pathologists who were blinded to SUVmax values. Obvious
dark-brown staining of cell nuclei was considered positive.
One thousand cells were counted in random fields of the
mucosal epithelium under 400× magnification. The index
of expression was calculated by the following formula:
Ki-67 = [(number of immunostained nuclei × 100) /
number of nuclei counted)].
2.4. Statistical analysis
Data are demonstrated as mean ± SD for normally
distributed continuous variables, median (minimum–
maximum) for skew distributed continuous variables,
and frequencies for categorical variables. The Pearson
chi-square test was performed for the comparison of
categorical variables. Continuous variables were compared
by Kruskal–Wallis test. To determine the factors correlated
with SUVmax, the Spearman test and Mann–Whitney U
test were performed. Receiver operating characteristic
(ROC) curve analysis was used to determine the predictive
value of SUVmax when deciding the malignant potential
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Figure 1. Scattered plot of Ki-67 and SUVmax values of study
cohort (n = 31).
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Table 1. Baseline characteristics of the patients.
Characteristics

Value

Age, years, median ± SD (range)

68.5 ± 10.6 (46–86)

Male/female, n

18/4

Diameter, median ± SD (range)

1.56 ± 1.3 cm (0.4–6 cm)

Location, n (%)
Descending-sigmoid colon

19 (61.2%)

Rectum-anal canal

7 (22.6%)

Transverse colon

3 (9.7%)

Ascending colon

2 (6.5%)

4. Discussion
The factors that influence the level of metabolic activity in
the colon remain a major confounding problem. Glucose
transporters and hexokinase levels have shown to lead
to FDG accumulation in the colon (4). Even though
proliferative activity of cells throughout the gastrointestinal
tract is constant, it increases in inflammatory and

Diagnosis, n (%)
Hyperplastic polyp

4 (12.9%)

Adenomatous polyp

20 (64.5%)

Adenocarcinoma NOS

7 (22.6%)

and high-grade dysplasia group) than low-risk lesions
(hyperplastic polyp and low-grade dysplasia group)
(SUVmax value 11.8 (range: 2.7–34.3) and 5.3 (range:
2.0–13.7), respectively, P = 0.009). The ROC analysis
showed that SUVmax values are diagnostic in predicting
the malignant potential of colon polyps. The threshold
SUVmax value was found to be 7.05. At this value
sensitivity was 80% and specificity was 71.4%. Positive
and negative predictive values were 53.3% and 87.5%,
respectively (Figure 2).

Dysplasia, n (%)
4 (12.9%)

Low grade

16 (51.6%)

High grade

11 (35.5%)

ROC Curve

1.0

0.8

SUVmax was found to be correlated with diagnosis.
The median SUVmax value of adenocarcinoma was
significantly higher than the median SUVmax value of both
adenomatous and hyperplastic polyps (P < 0.001 and P <
0.001). The median SUVmax value of adenomatous polyps
was significantly higher than hyperplastic polyps’ (P =
0.010). Dysplasia degree was also correlated with median
SUVmax value. Both low- and high-grade dysplasia
showed higher median SUVmax values compared to the
lacking dysplasia (P < 0.001 and P = 0.020, respectively).
Furthermore, the median SUVmax value of high-grade
dysplasia was significantly higher than that of the lowgrade dysplasia group (P < 0.001) (Table 2).
Finally, median SUVmax value was found to be
significantly higher in high-risk lesions (adenocarcinoma

Sensitivity

No
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0.4
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Figure 2. ROC curve showing the sensitivity and specificity of
SUVmax value (AUC: 0.86, 95% confidence interval: 0.71–1.00,
P = 0.001).

Table 2. SUVmax and Ki-67 values according to diagnosis and dysplasia degree.
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Characteristics

Median SUVmax (range)

Mean Ki-67 ± SD

Hyperplastic polyp (n = 4)
Adenomatous polyp (n = 20)
Adenocarcinoma (n = 7)

3.7 (2.0–7.6)
5.3 (2.3–21.9)
14.9 (4.8–34.4)

14.6 ± 5.8
17.9 ± 15.1
58.0 ± 28.2

Dysplasia negative (n = 4)
Low-grade dysplasia (n = 16)
High-grade dysplasia(n = 11)

3.0 (2.0–7.4)
5.7 (2.3–13.8)
11.9 (2.7–34.4)

14.6 ± 5.8
18.7 ± 16.8
42.2 ± 31.0
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neoplastic circumstances. It is reasonable in proliferating
cells to have increased glucose metabolism and high FDG
accumulation. Ki-67 protein expression appears during the
G1 phase of the cell cycle and diminishes after mitosis, and
thus it is a good marker of proliferation, demonstrating the
large spectrum of the cell cycle (5). Correlation between
proliferation markers and FDG uptake have been shown
in several other tumors such as breast cancer and nonHodgkin lymphoma (6,7). To the best of our knowledge
there is no literature investigating the correlation between
SUVmax and Ki-67 in colorectal neoplasms. In this
study we have demonstrated a significant correlation
between Ki-67 and SUVmax. Thus, we have proved that
proliferation degree is one of the components that leads
to FDG accumulation in cells of colorectal neoplasms
(Figure 3).
There has been great interest in identifying an
association between proliferating markers, such as Ki67, and tumor behavior in human malignancy. Higher
proliferation indexes have shown to be related to worse

outcome in colorectal carcinoma in several studies (8,9).
We have demonstrated significant correlation between
SUVmax and Ki-67 in colorectal neoplasms. The Ki-67
index of carcinomas was also significantly higher than that
of adenomatous and hyperplastic polyps. Thus, SUVmax
may predict the prognosis of a tumor in the colorectal
region. In fact, studies about the prognostic value of
SUVmax in colorectal carcinoma are limited. Riedl et al.
found that GLUT1, Ki-67, and p53 were all correlated with
SUVmax and higher SUVmax levels were correlated with
poorer prognosis in metastatic colorectal carcinoma (10).
However, Lee et al. did not find a relationship with high
FDG uptake and tumor recurrence or disease-free survival
in resectable colorectal cancer, but they recognized not
providing immunohistochemical information on glucose
metabolism (11). Although there are only 7 carcinoma
cases in our series, we think that investigation in larger
series and long follow-up with correlation between stage,
Ki-67, and SUVmax may contribute to better information
about this hypothesis.

Figure 3. FDG PET-CT image showing focal FDG uptake in ascending colon at the level of the hepatic flexura (SUVmax:
8.1) (A). The histopathologic examination of the same case was consistent with tubular adenoma with a Ki-67 index of 21%
(immunoperoxidase, 200×) (B). FDG PET-CT image showing focal FDG uptake in the rectum (SUVmax: 21.47) (C). The
histopathologic diagnosis was consistent with adenocarcinoma with a Ki-67 index of 80% (immunoperoxidase 200×) (D)
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It is thought that most of the sporadic colorectal
carcinomas evolve from adenomatous polyps and severe
dysplasia indicates increased risk of carcinoma (12).
Early detection of adenomas at a high risk of progression
is an effective approach to decrease colon cancer deaths.
Current screening methods lack specificity as they detect
many adenomas that will never progress to colorectal
carcinoma. In this study, although our sample number was
low, we have shown that high FDG uptake is significantly
correlated with high-risk lesions in the colorectal tract.
In this setting, FDG PET-CT may be useful in early
identification of colorectal premalignant lesions. In a
previous study adenomas with high-grade dysplasia were
reported to be more likely to be detected during PETCT scan, but in that study SUVmax was not compared
to dysplasia degree (13). Chen et al. found SUVmax
correlation with adenoma and carcinoma, but unlike this
study they did not use concomitant CT (14). Gutman et
al. succeeded to find a correlation between FDG uptake

intensity and severity of the lesion detected by FDG PETCT. The threshold mean SUVmax values for carcinoma (15
± 11.6 ) and low-grade dysplasia (8.84 ± 4.9) in that study
are close to this one’s (15). In a prospective study SUVmax
was found to be a risk factor for predicting carcinoma and
polyps (16). A recent study also determined that SUVmax
can display malignancy together with metabolic volume
(17). Nonetheless, there are several studies that were not
able to reach a significant correlation between SUVmax
and malignancy but recommended colonoscopy when
intense FDG accumulation is determined (18–21).
Even so, our results can indicate that high SUVmax
values determined by FDG PET-CT can predict malignancy
and prognosis in the colorectal region. Colonoscopy and
biopsy should always be performed whenever a focal
high FDG uptake is determined incidentally in a patient.
We think that the results of our study along with similar
further investigations can open a new debate for the use of
intriguing PET-CT colonography, at least in selected cases.
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